Drug intelligence / Profile preview

bezisterim

Development stage: Phase 3
Lead developer: BioVie
Modality: Small Molecules
Administration: Oral

Overview

Bezisterim (NE3107) is an investigational, orally bioavailable small molecule being developed by BioVie for the treatment of Long COVID, Alzheimer's disease, and Parkinson's disease. It acts as an anti-inflammatory and insulin-sensitizing agent that effectively crosses the blood-brain barrier. Its primary mechanism involves inhibiting Toll-like receptor 4 (TLR-4) driven activation of nuclear factor kappa B (NFκB) and modulating extracellular signal-regulated kinase (ERK) signaling. By targeting these pathways, bezisterim reduces the expression of pro-inflammatory cytokines such as IL-6, TNF, and IFNγ without being immunosuppressive. In Long COVID, it is specifically being evaluated for its potential to alleviate neurocognitive symptoms ("brain fog") and fatigue.

Brand names: Bezisterim
Other names: Triolex

Targets

MAPK3 (Mitogen-activated protein kinase 1)TLR4 (Toll-like receptor 4)LRP1 (Prolow-density lipoprotein receptor-related protein 1)SIRT2 (NAD-dependent protein deacetylase sirtuin-2)RPS6KA3 (RSK2)

Beyond the preview

Go deeper on bezisterim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bezisterim.

Explore the full profile